The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI
Open accessAbstract
Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation (OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with direct oral anticoagulants that decrease the risk of intracranial bleeding compared with vitamin K antagonists. Of note, approximately 5% to 10% of patients undergoing percutaneous coronary intervention have AF, which complicates antithrombotic therapy in daily practice, because the guidelines recommend that these patients also receive dual antiplatelet therapy (DAPT) to reduce the risk of ischemic complications. However, combining OAC with DAPT, a strategy also known as triple antithrombotic therapy, is known to increase the risk of bleeding compared with the use of OAC or DAPT alone. Studies of direct oral anticoagulants are now emerging that show the favorable safety profile of double antithrombotic therapy with OAC and a P2Y12 inhibitor in comparison with triple antithrombotic therapy including the use of vitamin K antagonists. The scope of this review is to provide an update on this topic as well as to discuss future directions in the management of antithrombotic therapy after percutaneous coronary intervention in AF patients requiring chronic OAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citationHeart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 1×
“As far as the type of OAC drug is concerned (first question), both the North American and European consensus documents agree with current ACC/AHA/HRS and ESC guidelines (11,12) that, in the absence of contraindications, DOACs should be preferred to VKAs due to the lower risk of bleeding previously demonstrated to be a…”
BackgroundApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“In AF patients who are deemed unsuitable for OAC with VKA, despite demonstration from the ACTIVE A trial that DAPT reduced the risk of major vascular events compared with aspirin monotherapy (18), the direct oral anticoagulant (DOAC) apixaban was found to reduce the risk of stroke or systemic embolism without increasi…”
BackgroundEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102 · cited 1×
“In AF patients who are deemed unsuitable for OAC with VKA, despite demonstration from the ACTIVE A trial that DAPT reduced the risk of major vascular events compared with aspirin monotherapy (18), the direct oral anticoagulant (DOAC) apixaban was found to reduce the risk of stroke or systemic embolism without increasi…”
BackgroundDewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719 · cited 2×
“The rationale for DAT as a default strategy is based on results of the 3 trials available at the time of publication that showed a more favorable safety profile compared with TAT (6,8,9).”
BackgroundMethodPrevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Self-citationDual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Self-citation
Cited by
Vranckx, P., Valgimigli, M., Eckardt, L., Tijssen, J., Lewalter, T., Gargiulo, G., Batushkin, V., Campo, G., Lysak, Z., Vakaliuk, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31872-0 · Cited by 685
Self-citationGargiulo, G., Goette, A., Tijssen, J., Eckardt, L., Lewalter, T., Vranckx, P., & Valgimigli, M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz732 · Cited by 318
Self-citationKumbhani, D. J., Cannon, C. P., Beavers, C. J., Bhatt, D. L., Cuker, A., Gluckman, T. J., Marine, J. E., Mehran, R., Messe, S. R., Patel, N. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.011 · Cited by 308
Self-citationAngiolillo, D. J., Bhatt, D. L., Cannon, C. P., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Granger, C. B., Holmes, D. R., Lopes, R. D., Mehran, R., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050438 · Cited by 302
Self-citationAntiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Self-citation
Metadata
- Authors
- Capodanno, D., Huber, K., Mehran, R., Lip, G. Y. H., Faxon, D. P., Granger, C. B., Vranckx, P., Lopes, R. D., Montalescot, G., Cannon, C. P., Ten Berg, J., Gersh, B. J., Bhatt, D. L., & Angiolillo, D. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 74
- Issue
- 1
- Pages
- 83-99
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2953934063
- Cited by
- 169
- References
- 13
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. https://app.cochat.ai/papers/10.1016/j.jacc.2019.05.016
- The paper
- Capodanno, D., Huber, K., Mehran, R., Lip, G. Y. H., Faxon, D. P., Granger, C. B., Vranckx, P., Lopes, R. D., Montalescot, G., Cannon, C. P., Ten Berg, J., Gersh, B. J., Bhatt, D. L., & Angiolillo, D. J. (2019). Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2019.05.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.